Prices delayed by at least 15 minutes | Print
Insmed (INSM)
Common SharesThis share can be held in a Dealing accountISALifetime ISAJISASIPP
Company profile
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
Address
700 US Highway 202/206
Bridgewater
NJ
USA
08807
Telephone
+1 908 977-9900
Forecast key dates
| Name | Key Date |
|---|---|
| Insmed Inc Fourth Quarter Earnings Conference Call for 2024 | 2025-02-21T08:30:00 |
| Insmed Inc Fourth Quarter Earnings Results for 2024 | 2025-02-21T00:00:00 |
| Insmed Inc Annual Report for 2024 | 2025-02-21T00:00:00 |
| Insmed Inc Third Quarter Earnings Conference Call for 2024 | 2024-10-25T08:30:00 |
| Insmed Inc Third Quarter Earnings Results for 2024 | 2024-10-25T00:00:00 |
| Insmed Inc Second Quarter Earnings Conference Call for 2024 | 2024-08-02T08:30:00 |
| Insmed Inc Second Quarter Earnings Results for 2024 | 2024-08-02T00:00:00 |
| Insmed Inc Annual General Meeting for 2024 | 2024-05-10T09:00:00 |
| Insmed Inc First Quarter Earnings Conference Call for 2024 | 2024-05-09T08:00:00 |
| Insmed Inc First Quarter Earnings Result for 2024 | 2024-05-09T00:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| The Barclays 26th Annual Global Healthcare Conference | 2024-03-13T16:35:00 |
| The Leerink Partners Global Biopharma Conference | 2024-03-12T13:00:00 |
| The TD Cowen 44th Annual Health Care Conference | 2024-03-04T14:50:00 |
| Insmed Inc Fourth Quarter Earnings Conference Call for 2023 | 2024-02-22T08:30:00 |
| Insmed Inc Fourth Quarter Earnings Result for 2023 | 2024-02-22T00:00:00 |
| Insmed Inc Annual Report for 2023 | 2024-02-22T00:00:00 |
| Insmed Inc Third Quarter Earnings Conference Call for 2023 | 2023-10-26T08:30:00 |
| Insmed Inc Third Quarter Earnings Result for 2023 | 2023-10-26T00:00:00 |
| Insmed Inc Second Quarter Earnings Conference Call for 2023 | 2023-08-03T08:30:00 |
| Insmed Inc Second Quarter Earnings Result for 2023 | 2023-08-03T00:00:00 |
| Insmed Inc Annual General Meeting for 2023 | 2023-05-11T09:00:00 |
| Insmed Inc First Quarter Earnings Conference Call for 2023 | 2023-05-04T08:30:00 |
| Insmed Inc First Quarter Earnings Result for 2023 | 2023-05-04T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.